U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07611812) titled 'Real-World Patterns of Utilization of Lenalidomide-based Triplet Regimens in FIrst RElapsed Multiple Myeloma Patients: Evidence From Medical Record Review' on May 14.
Brief Summary: To compare progression-free survival (PFS) in patients with first-relapse multiple myeloma treated with Rd-based "triplets" (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs. Elotuzumab + Rd (EloRd) vs. Ixazomib + Rd (IxaRd))
Study Start Date: Feb. 04, 2021
Study Type: OBSERVATIONAL
Condition:
Multiple Mieloma
First Relpase
Rd-base Triplet
Recruitment Status: COMPLETED
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia
Information prov...